Stay updated on Dostarlimab Combo in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Dostarlimab Combo in Endometrial Cancer Clinical Trial page.

Latest updates to the Dostarlimab Combo in Endometrial Cancer Clinical Trial page
- Check6 days agoChange DetectedA new NIH grant/contract identifier was added to the study's list of other identifiers, indicating NIH funding attribution for the RUBY trial.SummaryDifference0.0%

- Check13 days agoChange DetectedThe author list in the Publications citation for the Dostarlimab NEJM paper has been deleted, altering the attribution shown for that study reference.SummaryDifference0.1%

- Check20 days agoChange DetectedA new NEJM publication citation for Dostarlimab in primary advanced or recurrent endometrial cancer was added, listing authors and article details. The page revision history was updated from v3.6.4 to v3.6.5.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4 on the page, signaling a recent internal update to the site's revision. No visible content or user-facing changes are indicated.SummaryDifference0.0%

- Check48 days agoChange DetectedA new publication citation has been added under Publications: 'Molecular Testing in Primary Advanced or Recurrent Endometrial Cancer: A Cost-Effectiveness Analysis' (JCO Precis Oncol, 2026). This update documents related research connected to the RUBY study.SummaryDifference0.0%

- Check63 days agoChange DetectedTwo new scholarly references were added to the record, increasing the study's cited literature on dostarlimab-based therapy in endometrial cancer. The record revision was updated from v3.6.0 to v3.6.3.SummaryDifference0.1%

Stay in the know with updates to Dostarlimab Combo in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dostarlimab Combo in Endometrial Cancer Clinical Trial page.